Since Pain Therapeutics Inc. (NASDAQ:PTIE) and Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pain Therapeutics Inc.	N/A	0.00	N/A	-1.16	0.00
Clementia Pharmaceuticals Inc.	N/A	0.00	50.56M	-2.03	0.00

Demonstrates Pain Therapeutics Inc. and Clementia Pharmaceuticals Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 provides us Pain Therapeutics Inc. and Clementia Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Pain Therapeutics Inc.	0.00%	-68.4%	-63.1%
Clementia Pharmaceuticals Inc.	0.00%	-40.7%	-38.2%

Liquidity

Pain Therapeutics Inc.’s Current Ratio is 24 while its Quick Ratio is 24. On the competitive side is, Clementia Pharmaceuticals Inc. which has a 10 Current Ratio and a 10 Quick Ratio. Pain Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Clementia Pharmaceuticals Inc.

Insider and Institutional Ownership

Institutional investors held 24.4% of Pain Therapeutics Inc. shares and 84.1% of Clementia Pharmaceuticals Inc. shares. 0.9% are Pain Therapeutics Inc.’s share held by insiders. Comparatively, insiders own roughly 5.69% of Clementia Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Pain Therapeutics Inc.	-1.64%	2.56%	8.11%	22.45%	-81.54%	41.18%
Clementia Pharmaceuticals Inc.	-1.19%	89.48%	80.32%	165.46%	51.83%	118.96%

For the past year Pain Therapeutics Inc.’s stock price has smaller growth than Clementia Pharmaceuticals Inc.

Pain Therapeutics, Inc., a biopharmaceutical company, develops drugs for treating nervous system in the United States. The companyÂ’s lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. It also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat AlzheimerÂ’s disease and other neurological disorders. The company was founded in 1998 and is based in Austin, Texas.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. The company is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.